Devyser advances U.S. clinical strategy with first patient enrolled in Devyser Accept cfDNA study
Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical...
Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical...
Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its...
With the IVDR transition approaching, European clinical laboratories are preparing for changes that...
The supply of anti-D immunoglobulin, a prophylactic cornerstone of maternal care, has come under...
RhD incompatibility remains a critical concern in prenatal care, with the potential to cause...
Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation...
Devyser, a pioneer in advanced genetic testing solutions, proudly announces the global launch of...
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a significant...
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation...
Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for...
Devyser has launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution designed...